Medical Terminology

norepinephrine-dopamine reuptake inhibitors (NDRIs)

« Back to Glossary Index

NDRIs (norepinephrine-dopamine reuptake inhibitors) are medications that block the reabsorption (reuptake) of specific neurotransmitters (norepinephrine and dopamine) after they have been excreted from a nerve cell. This inhibition of the reabsorption results in more activity of these specific neurotransmitters throughout the brain. NDRIs are commonly used to treat clinical depression, ADHD and narcolepsy. NDRI medications approved for use in the U.S. include methylphenidate (Ritalin), bupropion (Wellbutrin) and solriamfetol (Sunosi).


The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.